美国 · SEC FORM 4
Passage BIO, Inc.
PASG · Nasdaq · CIK 0001787297 · Healthcare · Biotechnology
内部人信号
1 位买方 · 1 条买入交易行 · $206.2K 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ 角色得分低 · 买入者中职位最高的是：TenPercentOwner（CEO、董事长和持股 10% 以上的股东得分最低）
- ⚠ Purchase activity is becoming less recent
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 43.2
- 43.1
- 43.0
- 43.0
- 42.9
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -26.0%
- 3M
- -17.3%
- 6M
- -62.7%
- 12M
- -55.4%
波动率与流动性
- 波动率
- 126.7%
- Beta
- —
- 平均每日成交额
- USD 90,698
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- —
- ROE
- -242.7%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：ROE · 财年截止日：2025-12-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 90,840
- 上期报告
- 97,008
- 日均成交量
- 24,739
- 回补天数
- 3.7
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 50,055 | USD 4.12 | USD 206,227 | SEC 申报 ↗ |
| 2025-09-15 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 11,900 | USD 6.99 | USD 83,181 | SEC 申报 ↗ |
| 2025-09-12 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 19,783 | USD 6.99 | USD 138,283 | SEC 申报 ↗ |
| 2025-09-11 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share (Common Stock) | 325 | USD 6.96 | USD 2,262 | SEC 申报 ↗ |
| 2025-07-24 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 66,423 | USD 5.71 | USD 379,275 | SEC 申报 ↗ |
| 2025-07-23 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 49,302 | USD 5.74 | USD 282,993 | SEC 申报 ↗ |
| 2025-07-22 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 13,123 | USD 5.44 | USD 71,389 | SEC 申报 ↗ |
| 2024-12-27 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share | 373,645 | USD 0.65 | USD 242,869 | SEC 申报 ↗ |
| 2024-11-27 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 29,300 | USD 0.67 | USD 19,631 | SEC 申报 ↗ |
| 2024-11-26 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common Stock | 167,055 | USD 0.71 | USD 118,609 | SEC 申报 ↗ |
| 2024-11-25 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 259,998 | USD 0.56 | USD 145,599 | SEC 申报 ↗ |
| 2023-06-28 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | 买入 (P) | Common Stock | 575,195 | USD 0.84 | USD 483,164 | SEC 申报 ↗ |
| 2023-06-27 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | 买入 (P) | Common Stock | 617,382 | USD 0.84 | USD 518,601 | SEC 申报 ↗ |
| 2022-05-04 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | 买入 (P) | Common Stock | 303,500 | USD 1.94 | USD 588,790 | SEC 申报 ↗ |
| 2022-05-03 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC | 买入 (P) | Common Stock | 221,500 | USD 1.93 | USD 427,495 | SEC 申报 ↗ |
Form 4 申报证据
5 transaction lines in the latest 365-day window; 119 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 50,055 | USD 4.12 | USD 206,227 | SEC 申报 ↗ |
| 2026-01-08 | Chou William | 卖出 (S) | Common Stock | 4,076 | USD 18.44 | USD 75,161 | SEC 申报 ↗ |
| 2026-01-08 | Chou William | 期权行权／转换 (M) | Common Stock | 10,000 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (5 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Lynx1 Capital Management LP; Nichols Weston | 买入 (P) | Common stock, $0.0001 par value per share ("Common Stock") | 50,055 | USD 4.12 | USD 206,227 | SEC 申报 ↗ |
| 2026-01-08 | Chou William | 卖出 (S) | Common Stock | 4,076 | USD 18.44 | USD 75,161 | SEC 申报 ↗ |
| 2026-01-08 | Chou William | 期权行权／转换 (M) | Common Stock | 10,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-08 | Borthwick Kathleen | 卖出 (S) | Common Stock | 2,062 | USD 18.44 | USD 38,023 | SEC 申报 ↗ |
| 2026-01-08 | Borthwick Kathleen | 期权行权／转换 (M) | Common Stock | 5,000 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PASG |
| CIK | 0001787297 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 119 transaction lines from 2020-02-28 to 2026-06-25 45 P purchase lines · 43 S sale lines · 31 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.